Repros Therapeutics, Inc. (RPRX)

[spartex]

Does anyone have an idea what a partner might pay for ex-US rights for Androxal? The reason I ask is we have a 140 mil market cap company with $30 mil in the bank, and most of us bulls believe the stock should be closer to $200-250 market cap based on the recent results (androxal and proellex) and safety news on Proellex. It's as if the street is assigning zero value to Androxal, and very little to Proellex too. I know rfj and others believe that part of the problem is that JP isn't providing enough visibility to wall street. I can almost do a one for two (regn for rprx) trade with my REGN shares now that they are back up to almost $21!